Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.

MLA

Hovingh, G.Kees, et al. “Alirocumab Dosing Patterns during 40 Months of Open-Label Treatment in Patients with Heterozygous Familial Hypercholesterolemia.” Journal of Clinical Lipidology, vol. 12, no. 6, Nov. 2018, pp. 1463–70. EBSCOhost, https://doi.org/10.1016/j.jacl.2018.08.011.

APA

Hovingh, G. K., Guyton, J. R., Langslet, G., Dufour, R., Baccara-Dinet, M. T., Din-Bell, C., Manvelian, G., & Farnier, M. (2018). Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 12(6), 1463–1470. https://doi.org/10.1016/j.jacl.2018.08.011

Chicago

Hovingh, G. Kees, John R. Guyton, Gisle Langslet, Robert Dufour, Marie T. Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, and Michel Farnier. 2018. “Alirocumab Dosing Patterns during 40 Months of Open-Label Treatment in Patients with Heterozygous Familial Hypercholesterolemia.” Journal of Clinical Lipidology 12 (6): 1463–70. doi:10.1016/j.jacl.2018.08.011.